Alteration of mTOR signaling occurs early in the progression of Alzheimer disease (AD): Analysis of brain from subjects with pre-clinical AD, amnestic mild cognitive impairment and late-stage AD

Journal of Neurochemistry

Volumn 133, Issue 5, 2015, Pages 739-749

  Tramutola, Antonella ^a   Triplett, Judy C ^b   Di Domenico, Fabio ^a   Niedowicz, Dana M ^c   Murphy, Michael P ^c   Coccia, Raffaella ^a   Perluigi, Marzia ^a   Allan Butterfield, D ^b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF KENTUCKY   (United States)

^c UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Alzheimer disease progression; amnestic Mild Cognitive Impairment (MCI); mTOR signaling, autophagy; Preclinical Alzheimer disease

Indexed keywords

BECLIN 1; BRAIN PROTEIN; GLYCOGEN SYNTHASE KINASE 3BETA; INITIATION FACTOR 4E BINDING PROTEIN 1; INSULIN RECEPTOR SUBSTRATE 1; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN LC 3; PROTEIN P70S6K; TAU PROTEIN; TENSIN; UNCLASSIFIED DRUG; AMYLOID BETA PROTEIN; MTOR PROTEIN, HUMAN; ONCOPROTEIN; TARGET OF RAPAMYCIN KINASE;

AGED; ALZHEIMER DISEASE; ARTICLE; AUTOPHAGY; BRAIN DISEASE; CONTROLLED STUDY; ENZYME ACTIVATION; HUMAN; HUMAN TISSUE; INFERIOR PARIETAL LOBULE; INSULIN RESISTANCE; MILD COGNITIVE IMPAIRMENT; NEUROPATHOLOGY; OXIDATIVE STRESS; PRECLINICAL ALZHEIMER DISEASE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; AMNESIA; BRAIN CHEMISTRY; DISEASE COURSE; FEMALE; MALE; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; PSYCHOLOGY; VERY ELDERLY;

AGED, 80 AND OVER; ALZHEIMER DISEASE; AMNESIA; AMYLOID BETA-PEPTIDES; AUTOPHAGY; BRAIN CHEMISTRY; DISEASE PROGRESSION; FEMALE; HUMANS; INSULIN RESISTANCE; MALE; MILD COGNITIVE IMPAIRMENT; ONCOGENE PROTEIN V-AKT; PHOSPHATIDYLINOSITOL 3-KINASES; SIGNAL TRANSDUCTION; TAU PROTEINS; TOR SERINE-THREONINE KINASES;

EID: 84928012290     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/jnc.13037     Document Type: Article

References (52)

1. Aluise C. D., Robinson R. A., Beckett T. L., Murphy M. P., Cai J., Pierce W. M., Markesbery W. R., and, Butterfield D. A., (2010). Preclinical Alzheimer disease: brain oxidative stress, Abeta peptide and proteomics. Neurobiol. Dis. 39, 221-228.
2. Aluise C. D., Robinson R. A., Cai J., Pierce W. M., Markesbery W. R., and, Butterfield D. A., (2011) Redox proteomics analysis of brains from subjects with amnestic mild cognitive impairment compared to brains from subjects with preclinical Alzheimer's disease: insights into memory loss in MCI. J. Alzheimers Dis. 23, 257-269.
3. An W. L., Cowburn R. F., Li L., Braak H., Alafuzoff I., Iqbal K., Iqbal I. G., Winblad B., and, Pei J. J., (2003) Up-regulation of phosphorylated/activated p70 S6 kinase and its relationship to neurofibrillary pathology in Alzheimer's disease. Am. J. Pathol. 163, 2645.
4. Baki L., Shioi J., Wen P., Shao Z., Schwarzman A., Gama-Sosa M., Neve R., and, Robakis N. K., (2004) PS1 activates PI3K thus inhibiting GSK-3 activity and tau overphosphorylation: effects of FAD mutations. EMBO J. 23, 2586-2596.
5. Bhaskar K., Miller M., Chludzinski A., Herrup K., Zagorski M., and, Lamb B. T., (2009) The PI3K-Akt-mTOR pathway regulates Abeta oligomer induced neuronal cell cycle events. Mol. Neurodegener. 16, 14.
6. Bhat R. V., Budd Haeberlein S. L., and, Avila J., (2004) Glycogen synthase kinase 3: a drug target for CNS therapies. J. Neurochem. 89, 1313-1317. Review.
7. Boura0Halfon S., and, Zick Y., (2009) Phosphorylation of IRS proteins, insulin action, and insulin resistance. Am. J. Physiol. Endocrinol. Metab. 296, E581-E591.
8. Bradley M. A., Markesbery W. R., and, Lovell M. A., (2010) Increased levels of 4-hydroxynonenal and acrolein in the brain in preclinical Alzheimer disease. Free Radic. Biol. Med. 48, 1570-1576.
9. Butterfield D. A., and, Sultana R., (2007) Redox proteomics identification of oxidatively modified brain proteins in Alzheimer's disease and mild cognitive impairment: insights into the progression of this dementing disorder. J. Alzheimers Dis. 12, 61-72. Review.
10. Butterfield D. A., Drake J., Pocernich C., and, Castegna A., (2001) Evidence of oxidative damage in Alzheimer's disease brain: central role for amyloid beta-peptide. Trends Mol. Med. 7, 548-554. Review.
11. Butterfield D. A., Gnjec A., Poon H. F., Castegna A., Pierce W. M., Klein J. B., and, Martins R. N., (2006) Redox proteomics identification of oxidatively modified brain proteins in inherited Alzheimer's disease: an initial assessment. J. Alzheimers Dis. 10, 391-397.
12. Butterfield D. A., Di Domenico F., Swomley A. M., Head E., and, Perluigi M., (2014a) Redox proteomics analysis to decipher the neurobiology of Alzheimer-like neurodegeneration: overlaps in Down's syndrome and Alzheimer's disease brain. Biochem. J. 463, 177-189.
13. Butterfield D. A., Di Domenico F., and, Barone E., (2014b) Elevated risk of type 2 diabetes for development of Alzheimer disease: a key role for oxidative stress in brain. Biochim. Biophys. Acta 1842, 1693-1706.
14. Caccamo A., Majumder S., Richardson A., Strong R., and, Oddo S., (2010) Molecular interplay between mammalian target of rapamycin (mTOR), amyloid-beta, and Tau: effects on cognitive impairments. J. Biol. Chem. 285, 13107-13120.
15. Cenini G., Dowling A. L., Beckett T. L., et al,. (2012) Association between frontal cortex oxidative damage and beta-amyloid as a function of age in Down syndrome. Biochim. Biophys. Acta 1822, 130-138.
16. Cenini G., Fiorini A., Sultana R., Perluigi M., Cai J., Klein J. B., Head E., and, Butterfield D. A., (2014) An investigation of the molecular mechanisms engaged before and after the development of Alzheimer disease neuropathology in Down syndrome: a proteomics approach. Free Radic. Biol. Med. 76C, 89-95.
17. Chiang G. G., and, Abraham R.T., (2005) Phosphorylation of mammalian target of rampamycin (mTOR) at Ser-2448 is mediated by p70S6. J. Biol. Chem. 280, 25485-25490.
18. Craft S., (2005) Insulin resistance syndrome and Alzheimer's disease: age- and obesity-related effects on memory, amyloid, and inflammation. Neurobiol. Aging 26 (Suppl 1), 65-69.
19. Craft S., (2012) Alzheimer disease: insulin resistance and AD-extending the translational path. Nat. Rev. Neurol. 8, 360-362.
20. De Felice F. G., Vieira M. N., Bomfim T. R., Decker H., Velasco P. T., Lambert M. P., Viola K. L., Zhao W. Q., Ferreira S. T., and, Klein W. L., (2009) Protection of synapses against Alzheimer's-linked toxins: insulin signaling prevents the pathogenic binding of Abeta oligomers. Proc. Natl Acad. Sci. USA 106, 7678.
21. De la Monte S. M., (2012) Brain insulin resistance and deficiency as therapeutic targets in Alzheimer's disease. Curr. Alzheimer Res. 9, 35-66. Review.
22. Dhand R., Hiles I., Panayotou G., et al,. (1994) PI 3-kinase is a dual specificity enzyme: autoregulation by an intrinsic protein-serine kinase activity. EMBO J. 13, 522-533.
23. Di Domenico F., Coccia R., Cocciolo A., et al,. (2013) Impairment of proteostasis network in Down syndrome prior to the development of Alzheimer's disease neuropathology: redox proteomics analysis of human brain. Biochim. Biophys. Acta 1832, 1249-1259.
24. Farr S. A., Ripley J. L., Sultana R., Zhang Z., Niehoff M. L., Platt T. L., Murphy M. P., Morley J. E., Kumar V., and, Butterfield D. A., (2014) Antisense oligonucleotide against GSK-3β in brain of SAMP8 mice improves learning and memory and decreases oxidative stress: involvement of transcription factor Nrf2 and implications for Alzheimer disease. Free Radic. Biol. Med. 67, 387-395.
25. Griffin R. J., Moloney A., Kelliher M., Johnston J. A., Ravid R., Dockery P., O'Connor R., and, O'Neill C., (2005) Activation of Akt/PKB, increased phosphorylation of Akt substrates and loss and altered distribution of Akt and PTEN are features of Alzheimer's disease pathology. J. Neurochem. 93, 105-117.
26. Gupta A., and, Dey C. S., (2012) PTEN, a widely known negative regulator of insulin/PI3K signaling, positively regulates neuronal insulin resistance. Mol. Biol. Cell 23, 3882-3898.
27. Hara K., Maruki Y., Long X., Yoshino K., Oshiro N., Hidayat S., Tokunaga C., Avruch J., and, Yonezawa K., (2002) Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell 110, 177-189.
28. Holtzman D. M., Morris J. C., and, Goate A. M., (2011) Alzheimer's disease: the challenge of the second century. Sci. Transl. Med. 3, 77sr1.
29. Hong M., and, Lee V. M. Y., (1997) Insulin and insulin-like growth factor-1 regulate tau phosphorylation in cultured human neurons. J. Biol. Chem. 272, 19547-19553.
30. Iacono D., O'Brien R., Resnick S. M., Zonderman A. B., Pletnikova O., Rudow G., An Y., West M. J., Crain B., and, Troncoso J. C., (2008) Neuronal hypertrophy in asymptomatic Alzheimer disease. J. Neuropathol. Exp. Neurol. 67, 578-589.
31. Leslie N. R., and, Downes C. P., (2002) PTEN: the down side of PI 3-kinase signalling. Cell. Signal. 14, 285-295. Review.
32. Li S. Y., Fang C. X., Aberle N. S., 2nd, Ren B. H., Ceylan-Isik A. F., and, Ren J., (2005a) Inhibition of PI-3 kinase/Akt/mTOR, but not calcineurin signaling, reverses insulin-like growth factor I-induced protection against glucose toxicity in cardiomyocyte contractile function. J. Endocrinol. 186, 491-503.
33. Li X., Alafuzoff I., Soininen H., Winblad B., and, Pei J. J., (2005b) Levels of mTOR and its downstream targets 4E-BP1, eEF2, and eEF2 kinase in relationships with tau in Alzheimer's disease brain. FEBS J. 272, 4211-4220.
34. Ling D., and, Salvaterra P. M., (2009) A central role for autophagy in Alzheimer-type neurodegeneration. Autophagy 5, 738-740.
35. Lovestone S., and, Reynolds C. H., (1997) The phosphorylation of tau: a critical stage in neurodevelopment and neurodegenerative processes. Neuroscience 78, 309-324. Review.
36. Lyubartseva G., Smith J. L., Markesbery W. R., and, Lovell M. A., (2009) Alterations of zinc transporter proteins ZnT-1, ZnT-4 and ZnT-6 in preclinical Alzheimer's disease brain. Brain Pathol. 20, 343-350.
37. Majumder S., Richardson A., Strong R., and, Oddo S., (2011) Inducing autophagy by rapamycin before, but not after, the formation of plaques and tangles ameliorates cognitive deficits. PLoS ONE 6, e25416.
38. McMahon L. P., Choi K. M., Lin T. A., Abraham R. T., and, Lawrence Jr. J. C., (2002) The rapamycin-binding domain govern substrate selectivity by the mammalian target of rampamycin. Mol. Cell. Biol. 22, 7428-7438.
39. Moloney A. M., Griffin R. J., Timmons S., O'Connor R., Ravid R., and, O'Neill C., (2010) Defects in IGF-1 receptor, insulin receptor and IRS-1/2 in Alzheimer's disease indicate possible resistance to IGF-1 and insulin signalling. Neurobiol. Aging 31, 224-243.
40. Nixon R. A., (2013) The role of autophagy in neurodegenerative disease. Nat. Med. 19, 983-997.
41. O'Brien R. J., Resnick S. M., Zonderman A. B., et al,. (2009) Neuropathologic studies of the Baltimore Longitudinal Study of Aging (BLSA). J. Alzheimers Dis. 18, 665-675.
42. O'Neill C., Kiely A. P., Coakley M. F., Manning S., and, Long-Smith C. M., (2012) Insulin and IGF-1 signalling: longevity, protein homoeostasis and Alzheimer's disease. Biochem. Soc. Trans. 40, 721-727. Review
43. Perluigi M., Pupo G., Tramutola A., Cini C., Coccia R., Barone E., Head E., Butterfield D. A., and, Di Domenico F., (2014) Neuropathological role of PI3K/Akt/mTOR axis in Down syndrome brain. Biochim. Biophys. Acta 1842, 1144-1153.
44. Petersen R. C., (2004) Mild cognitive impairment as a diagnostic entity. J. Intern. Med. 256, 183-194. Review.
45. Pickford F., Masliah E., Britschgi M., et al,. (2008) The autophagy-related protein beclin 1 shows reduced expression in early Alzheimer disease and regulates amyloid beta accumulation in mice. J. Clin. Invest. 118, 2190-2199.
46. Querfurth H. W., and, LaFerla F. M., (2010) Alzheimer's disease. N. Engl. J. Med. 362 (4), 329-344.
47. Talbot K., Wang H. Y., Kazi H., et al,. (2012) Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J. Clin. Invest. 122, 1316-1338.
48. Townsend M., Mehta T., and, Selkoe D. J., (2007) Soluble Abeta inhibits specific signal transduction cascades common to the insulin receptor pathway. J. Biol. Chem. 282, 33305-33312.
49. West M. J., Kawas C. H., Stewart W. F., Rudow G. L., and, Troncoso J. C., (2004) Hippocampal neurons in pre-clinical Alzheimer's disease. Neurobiol. Aging 25, 1205-1212.
50. Yates S. C., Zafar A., Hubbard P., et al,. (2013) Dysfunction of the mTOR pathway is a risk factor for Alzheimer's disease. Acta Neuropathol. Commun. 1, 3-26.
51. Zhao W. Q., and, Townsend M., (2009) Insulin resistance and amyloidogenesis as common molecular foundation for type 2 diabetes and Alzheimer's disease. Biochim. Biophys. Acta 1792, 482-496. Review.
52. Zhao W. Q., De Felice F. G., Fernandez S., Chen H., Lambert M. P., Quon M. J., Krafft G. A., and, Klein W. L., (2008) Amyloid beta oligomers induce impairment of neuronal insulin receptors. FASEB J. 22, 246-260.